Aclaris Therapeutics: Wedbush cuts to neutral from outperform, target to $3 from $8
ACRS•Wedbush cut its rating on Aclaris Therapeutics to neutral from outperform and lowered its target price to $3 from $8.
Related News

OceanaGold drilling confirms deeper mineralization at Didipio mine
OGC•

Griffon Q4 revenue $490.9 million vs. IBES estimate of $480.7 million
GFF•

H World: StoneX raises target price to $64 from $60
HTHT•

Scotiabank: Raymond James raises target price to C$142.5 from C$139
BNS•

Chaince Digital Q3 revenue rises 92% on underwriter services growth
CD•